Rare Disease Treatment-Global Market Status and Trend Report 2016-2026

Table of Contents

Chapter 1 Overview of Rare Disease Treatment

• 1.1 Definition of Rare Disease Treatment in This Report
• 1.2 Commercial Types of Rare Disease Treatment
  • 1.2.1 Originator Drugs
  • 1.2.2 Generic Drugs
• 1.3 Downstream Application of Rare Disease Treatment
  • 1.3.1 Hospital Pharmacies
  • 1.3.2 Specialty Pharmacies
  • 1.3.3 Retail Pharmacies
• 1.4 Development History of Rare Disease Treatment
• 1.5 Market Status and Trend of Rare Disease Treatment 2016-2026
  • 1.5.1 Global Rare Disease Treatment Market Status and Trend 2016-2026
  • 1.5.2 Regional Rare Disease Treatment Market Status and Trend 2016-2026

Chapter 2 Global Market Status and Forecast by Regions

• 2.1 Market Development of Rare Disease Treatment 2016-2021
• 2.2 Production Market of Rare Disease Treatment by Regions
  • 2.2.1 Production Volume of Rare Disease Treatment by Regions
  • 2.2.2 Production Value of Rare Disease Treatment by Regions
• 2.3 Demand Market of Rare Disease Treatment by Regions
• 2.4 Production and Demand Status of Rare Disease Treatment by Regions
  • 2.4.1 Production and Demand Status of Rare Disease Treatment by Regions 2016-2021
  • 2.4.2 Import and Export Status of Rare Disease Treatment by Regions 2016-2021

Chapter 3 Global Market Status and Forecast by Types

• 3.1 Production Volume of Rare Disease Treatment by Types
• 3.2 Production Value of Rare Disease Treatment by Types
• 3.3 Market Forecast of Rare Disease Treatment by Types

Chapter 4 Global Market Status and Forecast by Downstream Industry

• 4.1 Demand Volume of Rare Disease Treatment by Downstream Industry
• 4.2 Market Forecast of Rare Disease Treatment by Downstream Industry

Chapter 5 Market Driving Factor Analysis of Rare Disease Treatment

• 5.1 Global Economy Situation and Trend Overview
• 5.2 Rare Disease Treatment Downstream Industry Situation and Trend Overview

Chapter 6 Rare Disease Treatment Market Competition Status by Major Manufacturers

• 6.1 Production Volume of Rare Disease Treatment by Major Manufacturers
• 6.2 Production Value of Rare Disease Treatment by Major Manufacturers
• 6.3 Basic Information of Rare Disease Treatment by Major Manufacturers
  • 6.3.1 Headquarters Location and Established Time of Rare Disease Treatment Major Manufacturer
  • 6.3.2 Employees and Revenue Level of Rare Disease Treatment Major Manufacturer
• 6.4 Market Competition News and Trend
  • 6.4.1 Merger, Consolidation or Acquisition News
  • 6.4.2 Investment or Disinvestment News
  • 6.4.3 New Product Development and Launch

Chapter 7 Rare Disease Treatment Major Manufacturers Introduction and Market Data

• 7.1 Novartis
  • 7.1.1 Company profile
  • 7.1.2 Representative Rare Disease Treatment Product
  • 7.1.3 Rare Disease Treatment Sales, Revenue, Price and Gross Margin of Novartis
• 7.2 Pfizer
  • 7.2.1 Company profile
  • 7.2.2 Representative Rare Disease Treatment Product
  • 7.2.3 Rare Disease Treatment Sales, Revenue, Price and Gross Margin of Pfizer
• 7.3 F. Hoffmann-La Roche
  • 7.3.1 Company profile
  • 7.3.2 Representative Rare Disease Treatment Product
  • 7.3.3 Rare Disease Treatment Sales, Revenue, Price and Gross Margin of F. Hoffmann-La Roche
• 7.4 Celgene
  • 7.4.1 Company profile
  • 7.4.2 Representative Rare Disease Treatment Product
  • 7.4.3 Rare Disease Treatment Sales, Revenue, Price and Gross Margin of Celgene
• 7.5 AbbVie
  • 7.5.1 Company profile
  • 7.5.2 Representative Rare Disease Treatment Product
  • 7.5.3 Rare Disease Treatment Sales, Revenue, Price and Gross Margin of AbbVie
• 7.6 Johnson & Johnson
  • 7.6.1 Company profile
  • 7.6.2 Representative Rare Disease Treatment Product
  • 7.6.3 Rare Disease Treatment Sales, Revenue, Price and Gross Margin of Johnson & Johnson
• 7.7 Takeda
  • 7.7.1 Company profile
  • 7.7.2 Representative Rare Disease Treatment Product
  • 7.7.3 Rare Disease Treatment Sales, Revenue, Price and Gross Margin of Takeda
• 7.8 Alexion
  • 7.8.1 Company profile
  • 7.8.2 Representative Rare Disease Treatment Product
  • 7.8.3 Rare Disease Treatment Sales, Revenue, Price and Gross Margin of Alexion
• 7.9 Novo Nordisk
  • 7.9.1 Company profile
  • 7.9.2 Representative Rare Disease Treatment Product
  • 7.9.3 Rare Disease Treatment Sales, Revenue, Price and Gross Margin of Novo Nordisk
• 7.10 Sanofi
  • 7.10.1 Company profile
  • 7.10.2 Representative Rare Disease Treatment Product
  • 7.10.3 Rare Disease Treatment Sales, Revenue, Price and Gross Margin of Sanofi
• 7.11 Bayer
  • 7.11.1 Company profile
  • 7.11.2 Representative Rare Disease Treatment Product
  • 7.11.3 Rare Disease Treatment Sales, Revenue, Price and Gross Margin of Bayer
• 7.12 Amgen
  • 7.12.1 Company profile
  • 7.12.2 Representative Rare Disease Treatment Product
  • 7.12.3 Rare Disease Treatment Sales, Revenue, Price and Gross Margin of Amgen
• 7.13 Allergan
  • 7.13.1 Company profile
  • 7.13.2 Representative Rare Disease Treatment Product
  • 7.13.3 Rare Disease Treatment Sales, Revenue, Price and Gross Margin of Allergan
• 7.14 Eisai
  • 7.14.1 Company profile
  • 7.14.2 Representative Rare Disease Treatment Product
  • 7.14.3 Rare Disease Treatment Sales, Revenue, Price and Gross Margin of Eisai
• 7.15 Bristol-Myers Squibb
  • 7.15.1 Company profile
  • 7.15.2 Representative Rare Disease Treatment Product
  • 7.15.3 Rare Disease Treatment Sales, Revenue, Price and Gross Margin of Bristol-Myers Squibb
• 7.16 Merck
• 7.17 Vertex Pharmaceuticals
• 7.18 Baxter
• 7.19 BioMarin
• 7.20 Teva Pharmaceutical Industries

Chapter 8 Upstream and Downstream Market Analysis of Rare Disease Treatment

• 8.1 Industry Chain of Rare Disease Treatment
• 8.2 Upstream Market and Representative Companies Analysis
• 8.3 Downstream Market and Representative Companies Analysis

Chapter 9 Cost and Gross Margin Analysis of Rare Disease Treatment

• 9.1 Cost Structure Analysis of Rare Disease Treatment
• 9.2 Raw Materials Cost Analysis of Rare Disease Treatment
• 9.3 Labor Cost Analysis of Rare Disease Treatment
• 9.4 Manufacturing Expenses Analysis of Rare Disease Treatment

Chapter 10 Marketing Status Analysis of Rare Disease Treatment

• 10.1 Marketing Channel
  • 10.1.1 Direct Marketing
  • 10.1.2 Indirect Marketing
  • 10.1.3 Marketing Channel Development Trend
• 10.2 Market Positioning
  • 10.2.1 Pricing Strategy
  • 10.2.2 Brand Strategy
  • 10.2.3 Target Client
• 10.3 Distributors/Traders List

Chapter 11 Report Conclusion

Chapter 12 Research Methodology and Reference

• 12.1 Methodology/Research Approach
  • 12.1.1 Research Programs/Design
  • 12.1.2 Market Size Estimation
  • 12.1.3 Market Breakdown and Data Triangulation
• 12.2 Data Source
  • 12.2.1 Secondary Sources
  • 12.2.2 Primary Sources